AC Immune Extends Alzheimer's Drug Pact With Eli Lilly
By Connor Hart
AC Immune amended its collaboration agreement with Eli Lilly, extending development of potential treatments for Alzheimer's disease and other neurodegenerative diseases.
The Swiss biopharmaceutical company said Tuesday that the revised agreement expands the partnership, which seeks to develop Tau aggregation-inhibitor small molecules.
Under the terms , AC Immune will receive an upfront payment of 10 million Swiss francs, equivalent to about $12.5 million, as well as additional payment tied to the initiation of Phase 1 clinical trials.
The company said it also remains eligible for more than 1.7 billion Swiss francs in development, regulatory and commercial milestones, in addition to tiered royalties in the low double digits.
The collaboration builds on a 2018 licensing deal between the companies and focuses on Tau-targeting small molecules designed to inhibit aggregation of the Tau protein, a key driver of neurodegeneration in Alzheimer's disease.
AC Immune shares rose 4.4%, to $2.82, in premarket trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 07, 2026 07:55 ET (11:55 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
United States